News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
683,831 Results
Type
Article (39011)
Company Profile (276)
Press Release (644544)
Section
Business (203944)
Career Advice (1988)
Deals (35370)
Drug Delivery (84)
Drug Development (80788)
Employer Resources (168)
FDA (16089)
Job Trends (14840)
News (344660)
Policy (32443)
Tag
Academia (2532)
Alliances (49076)
Alzheimer's disease (1215)
Approvals (16008)
Artificial intelligence (116)
Bankruptcy (352)
Best Places to Work (11503)
Biotechnology (196)
Breast cancer (107)
Cancer (901)
Cardiovascular disease (81)
Career advice (1658)
Cell therapy (198)
Clinical research (63936)
Collaboration (326)
Compensation (168)
COVID-19 (2523)
Cystic fibrosis (78)
Data (862)
Diabetes (134)
Diagnostics (6099)
Earnings (84183)
Employer resources (146)
Events (108978)
Executive appointments (247)
FDA (16533)
Funding (289)
Gene therapy (148)
GLP-1 (560)
Government (4318)
Healthcare (18662)
Infectious disease (2598)
Inflammatory bowel disease (102)
Interviews (309)
IPO (16272)
Job creations (3628)
Job search strategy (1417)
Layoffs (408)
Legal (7852)
Lung cancer (154)
Manufacturing (151)
Medical device (13152)
Medtech (13157)
Mergers & acquisitions (19120)
Metabolic disorders (365)
Neuroscience (1456)
NextGen Class of 2024 (6501)
Non-profit (4468)
Northern California (1206)
Obesity (217)
Opinion (176)
Patents (94)
People (56168)
Phase I (19826)
Phase II (28149)
Phase III (21021)
Pipeline (213)
Postmarket research (2555)
Preclinical (8431)
Radiopharmaceuticals (234)
Rare diseases (179)
Real estate (5896)
Regulatory (21450)
Research institute (2308)
Resumes & cover letters (350)
Southern California (1082)
Startups (3563)
United States (11673)
Vaccines (537)
Weight loss (161)
Date
Today (235)
Last 7 days (849)
Last 30 days (2909)
Last 365 days (35718)
2024 (30413)
2023 (40081)
2022 (51188)
2021 (55724)
2020 (54105)
2019 (46573)
2018 (35062)
2017 (32130)
2016 (31502)
2015 (37568)
2014 (31346)
2013 (26367)
2012 (28600)
2011 (29298)
2010 (27367)
Location
Africa (714)
Arizona (201)
Asia (37023)
Australia (6039)
California (2727)
Canada (1178)
China (210)
Colorado (117)
Connecticut (122)
Europe (79281)
Florida (394)
Georgia (100)
Illinois (306)
Indiana (177)
Kansas (95)
Maryland (515)
Massachusetts (2229)
Michigan (143)
Minnesota (250)
New Jersey (827)
New York (840)
North Carolina (665)
Northern California (1206)
Ohio (127)
Pennsylvania (747)
South America (1092)
Southern California (1082)
Texas (383)
Utah (80)
Washington State (321)
683,831 Results for "phoenix pharmalabs inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Phoenix PharmaLabs’ Lead Compound, PPL-138, Offers Promise as PTSD/AUD Treatment
Phoenix PharmaLabs, Inc. today announced that in vivo studies demonstrated that the company’s lead compound, PPL-138, reduced symptoms of PTSD and decreased alcohol consumption in a rat model of PTSD/AUD (alcohol abuse disorder).
September 14, 2023
·
4 min read
Press Releases
PreveCeutical Engages Phoenix Corporate Finance Inc. to Provide Advisory Services
October 18, 2024
·
4 min read
Biotech Bay
Phoenix Biotech Acquisition Corp. and CERo Therapeutics, Inc. Announce Close of Business Combination
Phoenix Biotech Acquisition Corp. and CERo Therapeutics, Inc., an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms announced that their previously announced business combination has closed, resulting in CERo becoming a publicly-traded company.
February 14, 2024
·
2 min read
Phoenix Children’s Research Institute Study Identifies FOXF1 Enhancers Involved in Rare Lung Disease
According to a study published in Nature Communications, research conducted at the Phoenix Children’s Research Institute at the University of Arizona College of Medicine — Phoenix, shows how frequent non-coding FOXF1 gene deletions that interfere with important DNA regulatory regions, called enhancers, can lead to Alveolar Capillary Dysplasia with Misalignment of Pulmonary Veins (ACDMPV), a rare, lethal, genetic lung disease which causes respiratory failure in newborns and infants.
June 19, 2024
·
4 min read
BioMidwest
Researchers at Phoenix Children’s First in the World to Produce Mouse Lungs in Rats
Research conducted at the Phoenix Children’s Research Institute at the University of Arizona College of Medicine — Phoenix reports the successful generation of a mouse lung in a rat, according to a paper published in the American Journal of Respiratory and Critical Care Medicine.
March 25, 2024
·
4 min read
BioMidwest
Study from Phoenix Children’s Research Institute Reveals New Way to Prevent Lung Cancer from Spreading
Research conducted at the Phoenix Children’s Research Institute at the University of Arizona College of Medicine — Phoenix shows normalizing cancer tumor vessels and alleviating low oxygen levels in the tumor microenvironment can improve the effectiveness of chemotherapy treatment in lung cancer, according to a paper published in EMBO Molecular Medicine.
April 25, 2024
·
4 min read
Phoenix PharmaLabs Awarded $8.7 Million Grant from NIDA to Study Compound for Treatment of Cocaine Use Disorder
Phoenix PharmaLabs, Inc. (https://phoenixpharmalabs.com), a private company developing potent, non-addictive treatments for pain and addiction, today announced the receipt of an $8.7 million grant from the National Institute on Drug Abuse (NIDA).
October 6, 2022
·
2 min read
Drug Development
Amylyx Pharmaceuticals Announces Topline Results From Global Phase 3 PHOENIX Trial of AMX0035 in ALS
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (“Amylyx” or the “Company”) today announced topline results from PHOENIX, a global, 48-week, randomized, placebo-controlled Phase 3 clinical trial of AMX0035 (sodium phenylbutyrate and taurursodiol [also known as ursodoxicoltaurine]; RELYVRIO® in the U.S., ALBRIOZA™ in Canada) in people living with amyotrophic lateral sclerosis (ALS).
March 8, 2024
·
15 min read
BioMidwest
Aclarion Expands Nociscan Access Into Phoenix With Key Opinion Leader Surgeon Advisor Juan Uribe, MD
Aclarion, Inc. announced that Nociscan is now available in the greater Phoenix, AZ market at the Barrow Neurological Institute with Dr. Juan Uribe and other area physicians treating chronic low back pain.
January 22, 2024
·
4 min read
Deals
RadNet’s Arizona Diagnostic Radiology Group Joint Venture Acquires Seven Outpatient Imaging Centers in Phoenix, Arizona
RadNet, Inc. announces that its joint ventured Arizona Diagnostic Radiology Group, LLC has acquired seven outpatient imaging centers in Phoenix Arizona from Evernorth Care Group.
January 24, 2024
·
2 min read
1 of 68,384
Next